{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:17:17Z","timestamp":1791051437968,"version":"4.1.0"},"reference-count":53,"publisher":"American Association for Cancer Research (AACR)","issue":"23","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Aromatase inhibitors are proving to be more effective than tamoxifen for postmenopausal estrogen receptor (ER)-positive breast cancer. However, the inevitable development of resistance to treatment is a concern. We investigated the effects of novel retinoic acid metabolism blocking agent, VN\/14-1, in overcoming letrozole resistance in long-term letrozole cultured (LTLC) cells. Compared with MCF-7 cells stably transfected with aromatase (MCF-7Ca), LTLC cells were no longer sensitive to growth inhibition by aromatase inhibitors. The HER-2\/phosphorylated mitogen-activated protein kinase (pMAPK) growth factor signaling pathways were activated, and ER\u03b1 and coactivator amplified in breast cancer 1 (AIB1) were up-regulated \u223c3-fold in LTLC cells. VN\/14-1 inhibited aromatase activity and growth values of in MCF-7Ca cells with IC50 of 8.5 and 10.5 nmol\/L, respectively. In human placental microsomes, aromatase activity was inhibited with IC50 of 8.0 pmol\/L. The IC50 in LTLC cells was 0.83 nmol\/L, similar to letrozole (IC50, 0.3 nmol\/L) in MCF-7Ca cells. LTLC cells were 10-fold more sensitive to growth inhibition by VN\/14-1 than MCF-7Ca cells. VN\/14-1 treatment effectively down-regulated ER\u03b1, AIB1, pMAPK, HER-2, cyclin D1, cyclin-dependent kinase 4 (CDK4), and Bcl2 and up-regulated cytokeratins 8\/18, Bad, and Bax. Tumor growth of LTLC cells in ovariectomized nude mice was independent of estrogens but was inhibited by VN\/14-1 (20 mg\/kg\/d; P &amp;lt; 0.002). Decreases in ER\u03b1, cyclin D1, CDK4, and pMAPK and up-regulation of cytokeratins, Bad, and Bax with VN\/14-1 in tumor samples may be responsible for the efficacy of this compound in inhibiting LTLC cell growth in vitro and in vivo. (Cancer Res 2006; 66(23): 11485-93)<\/jats:p>","DOI":"10.1158\/0008-5472.can-06-2168","type":"journal-article","created":{"date-parts":[[2006,12,4]],"date-time":"2006-12-04T17:52:48Z","timestamp":1165254768000},"page":"11485-11493","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Effects of Novel Retinoic Acid Metabolism Blocking Agent (VN\/14-1) on Letrozole-Insensitive Breast Cancer Cells"],"prefix":"10.1158","volume":"66","author":[{"given":"Aashvini","family":"Belosay","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Experimental Therapeutics, School of Medicine and the Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.H.","family":"Brodie","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Therapeutics, School of Medicine and the Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent C.O.","family":"Njar","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Therapeutics, School of Medicine and the Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2006,12,4]]},"reference":[{"key":"2022061622110264000_B1","unstructured":"Jenson E, Jordan C. The estrogen receptor, a model for molecular medicine. Clin Cancer Res\u20082003; 9: 1980\u20139."},{"key":"2022061622110264000_B2","doi-asserted-by":"crossref","unstructured":"Yue W, Mor G, Naftolin F, et al. Aromatase inhibitors in breast cancer. In: Robertson J, Nicholson R, Hayes D, editors. Endocrine therapy of breast cancer. London: Martin Dunitz Ltd.; 2002. p. 75\u2013106.","DOI":"10.1201\/b14733-8"},{"key":"2022061622110264000_B3","unstructured":"McGuire W. An update on estrogen and progesterone receptors in prognosis for primary and advanced breast cancer. In: Iacobelli S, King RJ, Lindner HR, Lippman ME, editors. Hormones and cancer. New York: Raven Press; 1980. p. 337\u201344."},{"key":"2022061622110264000_B4","doi-asserted-by":"crossref","unstructured":"Reed M, Owen A, Lai L, et al. In situ estrone synthesis in normal breast and breast tumor tissues: effect of treatment with 4-hydroxyandrostenedione. Int J Cancer\u20081989; 44: 233\u20137.","DOI":"10.1002\/ijc.2910440208"},{"key":"2022061622110264000_B5","unstructured":"van Landegham A, Portman J, Nabauurs M. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res\u20081985; 45: 2900\u20136."},{"key":"2022061622110264000_B6","doi-asserted-by":"crossref","unstructured":"Brodie A, Garrett W, Hendrickson J, Tsai-Morris C, Marcotte P, Robinson C. Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo. Steroids\u20081981; 38: 693\u2013702.","DOI":"10.1016\/0039-128X(81)90087-8"},{"key":"2022061622110264000_B7","doi-asserted-by":"crossref","unstructured":"Coombes C, Hall E, Gibson A. Randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med\u20082004; 350: 1081\u201392.","DOI":"10.1056\/NEJMoa040331"},{"key":"2022061622110264000_B8","doi-asserted-by":"crossref","unstructured":"Buzdar A. Superior efficacy of letrozole versus tamoxifen as first-line therapy. J Clin Oncol\u20082002; 20: 876\u20138.","DOI":"10.1200\/JCO.2002.20.3.876"},{"key":"2022061622110264000_B9","doi-asserted-by":"crossref","unstructured":"Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol\u20082001; 19: 2596\u2013606.","DOI":"10.1200\/JCO.2001.19.10.2596"},{"key":"2022061622110264000_B10","doi-asserted-by":"crossref","unstructured":"Goss P, Ingle J, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy. N Engl J Med\u20082003; 349: 1793\u2013802.","DOI":"10.1056\/NEJMoa032312"},{"key":"2022061622110264000_B11","doi-asserted-by":"crossref","unstructured":"Baum M, Buzdar A, Cuzick J. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer\u20082003; 98: 1802\u201310.","DOI":"10.1002\/cncr.11745"},{"key":"2022061622110264000_B12","unstructured":"Wakeling A, Nicholson R, Gee J. Prospects for combining hormonal and nonhormonal growth factor inhibition. Clin Cancer Res\u20082001; 7: 4350\u20135."},{"key":"2022061622110264000_B13","doi-asserted-by":"crossref","unstructured":"Benz C, Scott G, Sarup J, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2\/neu. Breast Cancer Res Treat\u20081992; 24: 85\u201395.","DOI":"10.1007\/BF01961241"},{"key":"2022061622110264000_B14","doi-asserted-by":"crossref","unstructured":"Nicholson R, Gee J. Estrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. Br J Cancer\u20082000; 82: 501\u201313.","DOI":"10.1054\/bjoc.1999.0954"},{"key":"2022061622110264000_B15","unstructured":"Lee A, Cui X, Oesterreich S. Cross-talk among estrogen receptor, epidermal growth factor, and insulin like growth factor signaling in breast cancer. Clin Cancer Res\u20082001; 12: 4429\u201335S; discussion 4411\u20134412S."},{"key":"2022061622110264000_B16","doi-asserted-by":"crossref","unstructured":"Shou J, Massarweh S, Osborne C, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2\/neu cross-talk in ER\/HER2-positive breast cancer. J Natl Cancer Inst\u20082004; 96: 926\u201335.","DOI":"10.1093\/jnci\/djh166"},{"key":"2022061622110264000_B17","unstructured":"Schiff R, Massarweh S, Shou J, Osborne C. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res\u20082003; 9: 447\u201354s."},{"key":"2022061622110264000_B18","unstructured":"Nicholson R, Gee J, Barrow D, Pamment J, Knowlden J, McClelland R. Endocrine resistance in breast cancer can involve a switch towards EGFR signaling pathways and a gain of sensitivity to an EGFR-selective tyrosine kinase inhibitor, ZD1839. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 1999."},{"key":"2022061622110264000_B19","doi-asserted-by":"crossref","unstructured":"Sabnis G, Jelovac D, Long B, Brodie A. The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res\u20082005; 65: 3903\u201310.","DOI":"10.1158\/0008-5472.CAN-04-4092"},{"key":"2022061622110264000_B20","doi-asserted-by":"crossref","unstructured":"Brodie A, Jelovac D, Sabnis G, Long B, Macedo L, Goloubeva O. Model systems: mechanisms involved in the loss of sensitivity to letrozole. J Steroid Biochem Mol Biol\u20082005; 95: 41\u20138.","DOI":"10.1016\/j.jsbmb.2005.04.026"},{"key":"2022061622110264000_B21","doi-asserted-by":"crossref","unstructured":"Jelovac D, Sabnis G, Long B, Macedo L, Goloubeva O, Brodie A. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. Cancer Res\u20082005; 65: 5380\u20139.","DOI":"10.1158\/0008-5472.CAN-04-4502"},{"key":"2022061622110264000_B22","doi-asserted-by":"crossref","unstructured":"Dragnev K, Rigas J, Dmitrovsky E. The retinoids and cancer prevention mechanisms. Oncologist\u20082000; 5: 361\u20138.","DOI":"10.1634\/theoncologist.5-5-361"},{"key":"2022061622110264000_B23","doi-asserted-by":"crossref","unstructured":"Goss P, Oza A, Goel R, et al. Liarozole fumarate (R85246): a novel imidazole in the treatment of receptor positive postmenopausal metastatic breast cancer. Breast Cancer Res Treat\u20082000; 59: 55\u201368.","DOI":"10.1023\/A:1006320122711"},{"key":"2022061622110264000_B24","doi-asserted-by":"crossref","unstructured":"Njar V. Cytochrome P450 retinoic acid 4-hydroxylase inhibitors: potential agents for cancer therapy. Mini Rev Med Chem\u20082002; 2: 261\u20139.","DOI":"10.2174\/1389557023406223"},{"key":"2022061622110264000_B25","doi-asserted-by":"crossref","unstructured":"Patel J, Huynh C, Handratta V, et al. Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice. J Med Chem\u20082004; 47: 6716\u201329.","DOI":"10.1021\/jm0401457"},{"key":"2022061622110264000_B26","unstructured":"Zhou D, Pompon D, Chen S. Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res\u20081990; 50: 6949\u201354."},{"key":"2022061622110264000_B27","doi-asserted-by":"crossref","unstructured":"Zhou D, Wang J, Chen E, Murai J, Siiteri P, Chen S. Aromatase gene is amplified in MCF-7 human breast cancer cells. J Steroid Biochem Mol Biol\u20081993; 46: 147\u201353.","DOI":"10.1016\/0960-0760(93)90289-9"},{"key":"2022061622110264000_B28","unstructured":"Yue W, Zhou D, Chen S, Brodie A. A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res\u20081994; 54: 5092\u20135."},{"key":"2022061622110264000_B29","doi-asserted-by":"crossref","unstructured":"Schwarzel W, Kruggel W, Brodie H. Studies on the mechanism of estrogen biosynthesis. The development of the enzyme system in the human placenta. Endocrinology\u20081973; 92: 866\u201380.","DOI":"10.1210\/endo-92-3-866"},{"key":"2022061622110264000_B30","doi-asserted-by":"crossref","unstructured":"Inkster S, Brodie A. Immunocytochemical studies of aromatase in early and full-term human placental tissues: comparison with biochemical assays. Biol Reprod\u20081989; 41: 889\u201398.","DOI":"10.1095\/biolreprod41.5.889"},{"key":"2022061622110264000_B31","doi-asserted-by":"crossref","unstructured":"Brodie A, Schwarzel W, Shaikh A, Brodie H. The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer. Endocrinology\u20081977; 100: 1684\u201395.","DOI":"10.1210\/endo-100-6-1684"},{"key":"2022061622110264000_B32","doi-asserted-by":"crossref","unstructured":"Brodie H, Kripliani K, Possanza G. Studies on the mechanisms of estrogen biosynthesis. VI. The stereochemistry of hydrogen elimination of C-2 during aromatization. J Am Chem Soc\u20081969; 91: 1241\u20133.","DOI":"10.1021\/ja01033a050"},{"key":"2022061622110264000_B33","unstructured":"Long B, Jelovac D, Thaintanawat A, Brodie A. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole. Long-term studies using the intratumoral aromatase postmenopausal breast cancer model. Clin Cancer Res\u20082002; 8: 2378\u201388."},{"key":"2022061622110264000_B34","doi-asserted-by":"crossref","unstructured":"Long B, Tilghman S, Yue W, Thaintanawat A, Grigoryev D, Brodie A. The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity. J Steroid Biochem Mol Biol\u20081998; 67: 293\u2013304.","DOI":"10.1016\/S0960-0760(98)00122-8"},{"key":"2022061622110264000_B35","doi-asserted-by":"crossref","unstructured":"Long B, Jelovac D, Haradatta V, et al. Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. J Natl Cancer Inst\u20082004; 96: 456\u201365.","DOI":"10.1093\/jnci\/djh076"},{"key":"2022061622110264000_B36","unstructured":"Katzenellenbogen B, Kendra K, Norman M, Berthois Y. Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res\u20081987; 47: 4355\u201360."},{"key":"2022061622110264000_B37","doi-asserted-by":"crossref","unstructured":"Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol\u20081998; 16: 462\u20139.","DOI":"10.1200\/JCO.1998.16.2.462"},{"key":"2022061622110264000_B38","doi-asserted-by":"crossref","unstructured":"Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer\u20082005; 93: 552\u20136.","DOI":"10.1038\/sj.bjc.6602738"},{"key":"2022061622110264000_B39","doi-asserted-by":"crossref","unstructured":"Yue W, Wang J, Conaway M, Li Y, Santen R. Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways. J Steroid Biochem Mol Biol\u20082003; 86: 265\u201374.","DOI":"10.1016\/S0960-0760(03)00366-2"},{"key":"2022061622110264000_B40","unstructured":"Kurokawa H, Arteaga C. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin Cancer Res\u20082003; 9: 511\u20135S."},{"key":"2022061622110264000_B41","doi-asserted-by":"crossref","unstructured":"Ciolino H, Wang T, Sathyamoorthy N. Inhibition of aromatase activity and expression in MCF-7 cells by the chemopreventive retinoid N-(4-hydroxy-phenyl)-retinamide. Br J Cancer\u20082000; 83: 333\u20137.","DOI":"10.1054\/bjoc.2000.1269"},{"key":"2022061622110264000_B42","doi-asserted-by":"crossref","unstructured":"Bhatnager A, Brodie A, Long B, Evans D, Miller W. Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors. J Steroid Biochem Mol Biol\u20082001; 76: 199\u2013202.","DOI":"10.1016\/S0960-0760(01)00050-4"},{"key":"2022061622110264000_B43","doi-asserted-by":"crossref","unstructured":"Simeone A, Tari A. How retinoids regulate breast cancer cell proliferation and apoptosis. Cell Mol Life Sci\u20082004; 61: 1475\u201384.","DOI":"10.1007\/s00018-004-4002-6"},{"key":"2022061622110264000_B44","doi-asserted-by":"crossref","unstructured":"Semeniuk E, Anchim T, Dzie\u0302cio J, Dbrowska M, Sawomir Wo czyn\u0303ski. Can transforming growth factor-1 and retinoids modify the activity of estradiol and antiestrogens in MCF-7 breast cancer cells? Acta Biochimica Polonica\u20082004; 51: 733\u201345.","DOI":"10.18388\/abp.2004_3558"},{"key":"2022061622110264000_B45","doi-asserted-by":"crossref","unstructured":"Teixeira C, Pratt C. CDK2 is a target for retinoic acid-mediated growth inhibition in MCF-7 human breast cancer cells. Mol Endocrinol\u20081997; 11: 1191\u2013202.","DOI":"10.1210\/mend.11.9.9977"},{"key":"2022061622110264000_B46","doi-asserted-by":"crossref","unstructured":"Pratt C, Niu M, White D. Differential regulation of protein expression, growth, and apoptosis by natural and synthetic retinoids. Cell Biochem\u20082003; 90: 692\u2013708.","DOI":"10.1002\/jcb.10682"},{"key":"2022061622110264000_B47","doi-asserted-by":"crossref","unstructured":"Zhou Q, Stetler-Stevenson M, Steeg P. Inhibition of cyclin D expression in human breast carcinoma cells by retinoids in vitro. Oncogene\u20081997; 15: 107\u201315.","DOI":"10.1038\/sj.onc.1201142"},{"key":"2022061622110264000_B48","doi-asserted-by":"crossref","unstructured":"Woelfle U, Sauter G, Santjer S, Brakenhoff R, Pantel K. Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer. Clin Cancer Res\u20082004; 10: 2670\u20134.","DOI":"10.1158\/1078-0432.CCR-03-0114"},{"key":"2022061622110264000_B49","doi-asserted-by":"crossref","unstructured":"Jing Y, Zhang J, Waxman S, Mira-y-Lopez R. Upregulation of cytokeratins 8 and 18 in human breast cancer T47D cells is retinoid-specific and retinoic acid receptor-dependent. Differentiation\u20081996; 60: 109\u201317.","DOI":"10.1046\/j.1432-0436.1996.6020109.x"},{"key":"2022061622110264000_B50","doi-asserted-by":"crossref","unstructured":"Korsching E, Packeisen J, Agelopoulos K, et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest\u20082002; 82: 1525\u201333.","DOI":"10.1097\/01.LAB.0000038508.86221.B3"},{"key":"2022061622110264000_B51","unstructured":"Rubin M, Fenig E, Rosenauer A, et al. 9-Cis retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein. Cancer Res\u20081994; 54: 6549\u201356."},{"key":"2022061622110264000_B52","doi-asserted-by":"crossref","unstructured":"Lu Q, Liu Y, Long B, Grigoryev D, Gimbel M, Brodie A. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer Res Treat\u20081999; 57: 183\u201392.","DOI":"10.1023\/A:1006225601046"},{"key":"2022061622110264000_B53","unstructured":"Brodie A, Jelovac D, Long B. Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens. Clin Cancer Res\u20082000; 9: 455\u20139S."}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/66\/23\/11485\/2557735\/11485.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/66\/23\/11485\/2557735\/11485.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T23:51:00Z","timestamp":1655423460000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/66\/23\/11485\/526600\/Effects-of-Novel-Retinoic-Acid-Metabolism-Blocking"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12,1]]},"references-count":53,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2006,12,4]]},"published-print":{"date-parts":[[2006,12,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-06-2168","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,12,1]]}}}